Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025
Integrated BioPharma (OTCQX: INBP) reported results for the quarter ended September 30, 2025. Revenue was $12.7 million, down 6.6% from $13.6 million a year earlier. Gross profit fell to $1.02 million from $1.37 million and operating income declined to $0.16 million from $0.49 million. Net income was $0.12 million, or $0.00 diluted per share, versus $0.26 million, or $0.01 diluted, in the prior-year quarter.
The company said its two largest Contract Manufacturing customers accounted for approximately 87% of revenue in Q3 2025 (85% in Q3 2024). Weighted average diluted shares were 31.42 million in Q3 2025. The company reiterated standard forward-looking cautionary language.
Integrated BioPharma (OTCQX: INBP) ha riportato i risultati del trimestre chiuso al 30 settembre 2025. Entrate sono state 12,7 milioni di dollari, in diminuzione del 6,6% rispetto ai 13,6 milioni di dollari dell'anno precedente. Utile lordo è sceso a 1,02 milioni da 1,37 milioni e reddito operativo è diminuito a 0,16 milioni da 0,49 milioni. Reddito netto è stato di 0,12 milioni, oppure 0,00 per azione diluita, rispetto a 0,26 milioni, o 0,01 diluito, nel trimestre dell'anno precedente.
L'azienda ha detto che i suoi due maggiori clienti di Contract Manufacturing hanno rappresentato circa l'87% dei ricavi nel Q3 2025 (85% nel Q3 2024). Le azioni ordinarie diluite medie pesate sono state 31,42 milioni nel Q3 2025. L'azienda ha ribadito il linguaggio cautelare forward-looking standard.
Integrated BioPharma (OTCQX: INBP) informó resultados del trimestre terminado al 30 de septiembre de 2025. Los ingresos fueron de 12,7 millones de dólares, una caída del 6,6% respecto a 13,6 millones de dólares en el año anterior. La utilidad bruta cayó a 1,02 millones desde 1,37 millones y el ingreso operativo descendió a 0,16 millones desde 0,49 millones. El ingreso neto fue de 0,12 millones, o 0,00 por acción diluida, frente a 0,26 millones, o 0,01 diluido, en el trimestre del año anterior.
La empresa dijo que sus dos mayores clientes de Contract Manufacturing representaron aproximadamente el 87% de los ingresos en el 3T 2025 (85% en el 3T 2024). Las acciones diluidas promediadas ponderadas fueron 31,42 millones en el 3T 2025. La empresa reiteró su lenguaje de advertencia prospectiva estándar.
Integrated BioPharma (OTCQX: INBP)가 2025년 9월 30일 종료 분기에 대한 실적을 발표했다. 매출은 1270만 달러로 전년 동기의 1360만 달러 대비 6.6% 감소했다. 총이익은 102만 달러로 떨어졌고 영업이익은 16만 달러로 49만 달러에서 하락했다. 순이익은 12만 달러로, 희석 주당 순이익은 0.00 달러였으며, 전년 동기의 26만 달러 또는 희석 주당 0.01 달러에 비해 낮았다.
회사에 따르면 두 개의 최대 Contract Manufacturing 고객이 2025년 3분기에 매출의 약 87%를 차지했고(2024년 3분기에는 85%), 가중 평균 희석 주식 수는 3,142만 주였다. 회사는 표준적인 미래 지향적 주의 문구를 재확인했다.
Integrated BioPharma (OTCQX: INBP) a publié les résultats du trimestre clos le 30 septembre 2025. Le chiffre d'affaires s'est élevé à 12,7 millions de dollars, en baisse de 6,6 % par rapport à 13,6 millions de dollars l'année précédente. La marge brute a chuté à 1,02 million contre 1,37 million et le résultat opérationnel a diminué à 0,16 million contre 0,49 million. Le revenu net était de 0,12 million, soit 0,00 par action diluée, contre 0,26 million, ou 0,01 dilué, au trimestre précédent.
L'entreprise a déclaré que ses deux plus grands clients de Contract Manufacturing représentaient environ 87% du chiffre d'affaires au T3 2025 (85% au T3 2024). Les actions diluées moyennes pondérées se situaient à 31,42 millions au T3 2025. L'entreprise a réitéré son langage d'avertissement prospectif standard.
Integrated BioPharma (OTCQX: INBP) berichtete die Ergebnisse für das Quartal zum 30. September 2025. Umsatz betrug 12,7 Millionen USD, ein Rückgang von 6,6% gegenüber 13,6 Millionen USD im Vorjahr. Bruttogewinn fiel auf 1,02 Millionen USD von 1,37 Millionen und betriebsgewinn sank auf 0,16 Millionen Von 0,49 Millionen. Nettogewinn betrug 0,12 Millionen, bzw. 0,00 USD je verwässerter Aktie, gegenüber 0,26 Millionen bzw. 0,01 verwässert je Aktie im Vorjahresquartal.
Das Unternehmen sagte, dass seine beiden größten Contract-Manufacturing-Kunden ca. 87% des Umsatzes im Q3 2025 ausmachten (85% im Q3 2024). Die gewichteten durchschnittlich verwässerten Aktien betrugen 31,42 Mio. im Q3 2025. Das Unternehmen bestätigte die standard Forward-Looking-Warnhinweise.
Integrated BioPharma (OTCQX: INBP) أصدرت نتائج الربع المنتهي في 30 سبتمبر 2025. كان الإيرادات 12.7 مليون دولار، بانخفاض 6.6% مقارنةً بـ 13.6 مليون دولار في العام السابق. الهامش الإجمالي انخفض إلى 1.02 مليون من 1.37 مليون و< b>الدخل التشغيلي انخفض إلى 0.16 مليون من 0.49 مليون. صافي الدخل كان 0.12 مليون، أو 0.00 للسهم المخفف، مقارنة بـ 0.26 مليون، أو 0.01 مخفف، في ربع السنة السابق.
قالت الشركة إن اثنين من أكبر عملائها في Contract Manufacturing شكلا نحو 87% من الإيرادات في الربع الثالث من 2025 (85% في الربع الثالث من 2024). كانت الأسهم المخففة الموزونة المتوسطة 31.42 مليون سهم في الربع الثالث من 2025. كرّرت الشركة عبارات التحذير القياسية المرتبطة بالنظرة المستقبلية.
- Net income of $0.12 million in Q3 2025
- Operating income remained positive at $0.16 million
- Operating income down ~66.7% year-over-year (from $0.49M to $0.16M)
- Net income down ~52.5% year-over-year (from $0.26M to $0.12M)
- Gross profit declined ~25.7% year-over-year (from $1.37M to $1.02M)
- High customer concentration: top two customers ≈87% of revenue in Q3 2025
HILLSIDE, NJ / ACCESS Newswire / November 10, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2025.
Revenue for the quarters ended September 30, 2025 was
For the quarters ended September 30, 2025 and 2024, the Company had net income of approximately
"Our revenue decreased by approximately
A summary of our financial results for the three months ended September 30, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
Three Months Ended | ||||||||
September 30, | ||||||||
2025 | 2024 | |||||||
Total revenue | $ | 12,689 | $ | 13,617 | ||||
Cost of sales | 11,670 | 12,246 | ||||||
Gross profit | 1,019 | 1,371 | ||||||
Selling and administrative expenses | 856 | 881 | ||||||
163 | 490 | |||||||
Interest income, net | 33 | 14 | ||||||
Income before income taxes | 196 | 504 | ||||||
Income tax expense, net | 73 | 245 | ||||||
Net income | $ | 123 | $ | 259 | ||||
Basic net income per common share | $ | 0.00 | $ | 0.01 | ||||
Diluted net income per common share | $ | 0.00 | $ | 0.01 | ||||
Weighted average common shares outstanding -basic | 31,059,610 | 30,099,610 | ||||||
Weighted average common shares outstanding -diluted | 31,421,338 | 30,649,977 | ||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What were Integrated BioPharma (INBP) revenues for Q3 2025?
Did Integrated BioPharma (INBP) report a profit in Q3 2025?
How did INBP's operating income change in Q3 2025 versus Q3 2024?
How concentrated is Integrated BioPharma's customer base in Q3 2025?
How many diluted shares were outstanding for INBP in Q3 2025?
